neuromarketing insights into branded allergy medication website design

44
1 www.otoihealth.com One to One Interactive, 2010. All rights reserved. Beyond the Voice of the Customer: Neuromarketing Insights into Patient Engagement with Pharmaceutical Brand Web Sites June 9, 2010 One to One Interactive, 2010. All rights reserved.

Upload: one-to-one

Post on 20-Jan-2015

1.337 views

Category:

Business


1 download

DESCRIPTION

One to One Health and OTOinsights present a first of it's kind study that shows how neuromarketing analysis can be garner new insights into patient engagement with branded drug sites. OTOinsights also presented this research at the 2010 Boston UPA mini-conference. More info at www.otoihealth.com

TRANSCRIPT

Page 1: Neuromarketing Insights into Branded Allergy Medication Website Design

1www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Beyond the Voice of the Customer: Neuromarketing Insights into Patient Engagement with Pharmaceutical Brand Web Sites

June 9, 2010

One to One Interactive, 2010. All rights reserved.

Page 2: Neuromarketing Insights into Branded Allergy Medication Website Design

2www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Live Tweeting Tags

@OnetoOneHealth@OTOinsights@banderlin

#miniUPA#neuromarketing#ePharma#eHealth

Page 3: Neuromarketing Insights into Branded Allergy Medication Website Design

3www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Agenda

Fundamentals of Neuromarketing

Insights: Allergy Category Competitive Benchmarking Analysis

Wrap Up

Questions & Answers

Page 4: Neuromarketing Insights into Branded Allergy Medication Website Design

4www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Fundamentals of Neuromarketing

Page 5: Neuromarketing Insights into Branded Allergy Medication Website Design

5www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 6: Neuromarketing Insights into Branded Allergy Medication Website Design

6www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 7: Neuromarketing Insights into Branded Allergy Medication Website Design

7www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 8: Neuromarketing Insights into Branded Allergy Medication Website Design

8www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 9: Neuromarketing Insights into Branded Allergy Medication Website Design

9www.otoihealth.com One to One Interactive, 2010. All rights reserved.fMR

I

Page 10: Neuromarketing Insights into Branded Allergy Medication Website Design

10www.otoihealth.com One to One Interactive, 2010. All rights reserved.EEG

Page 11: Neuromarketing Insights into Branded Allergy Medication Website Design

11www.otoihealth.com One to One Interactive, 2010. All rights reserved.Bio

-Feed

back

Page 12: Neuromarketing Insights into Branded Allergy Medication Website Design

12www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Quantemo™

Page 13: Neuromarketing Insights into Branded Allergy Medication Website Design

13www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 14: Neuromarketing Insights into Branded Allergy Medication Website Design

14www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 15: Neuromarketing Insights into Branded Allergy Medication Website Design

15www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Page 16: Neuromarketing Insights into Branded Allergy Medication Website Design

16www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Quantemo Engagement Index (QEI) combines data from traditional user research, information processing models, and socio-cultural models to correlate people’s felt experience of their emotions when interacting with media stimuli with their behavioral/physiological responses.

Quantemo™ Engagement Index (QEI)

Σ = Quantemo Behavioral Index + Quantemo Neurological Index + Emotional Tagging

Page 17: Neuromarketing Insights into Branded Allergy Medication Website Design

17www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Wrap Up

Page 18: Neuromarketing Insights into Branded Allergy Medication Website Design

18www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insights: Allergy Category Competitive Benchmarking Analysis

Page 19: Neuromarketing Insights into Branded Allergy Medication Website Design

19www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Overview of StudyIn this study, we compared participants’ levels of engagement with 8 static web pages from branded allergy medication web sites – both OTC and prescription brands

• Static web pages displayed in a random order• After all stimuli were shown, participants fill out emotional and rating surveys• Qualitative interview conducted• Participants were male and female, ages 25-55, current allergy suffers

Page 20: Neuromarketing Insights into Branded Allergy Medication Website Design

20www.otoihealth.com One to One Interactive, 2010. All rights reserved.

OVERALL ENGAGEMENT

Page 21: Neuromarketing Insights into Branded Allergy Medication Website Design

21www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Overall Engagement

Zyrtec

Claritin

Benedryl

Astepro

Xyzal

Astelin

Veramyst

Nasonex

-0.50

0.00

0.50

1.00

1.50

2.00

2.50

3.00

2.49

2.14

1.22

0.400.21

-0.05 -0.07-0.18

Quantemo Engagement Index

Site

QEI

• Multiple Calls to Action and navigations • Pleasing colors• OTC Status• Outdoor activity

• Page is mostly ISI• Single, lengthy

navigation• Single type of Call to

Action

Page 22: Neuromarketing Insights into Branded Allergy Medication Website Design

22www.otoihealth.com One to One Interactive, 2010. All rights reserved.

The Elements of Engagement

Zyrtec Xyzal Nasonex Astepro Benedryl Claritin Astelin Veramyst0.00

0.20

0.40

0.60

0.80

1.00

1.20

1.40 1.33 1.33

1.12

0.730.67

0.59

0.230.15

Quantemo Neurological Index

Site

QN

I

Actionable insights gained by triangulating on the consumer experience

Xyzal had high neurological engagement, but low overall engagement

Page 23: Neuromarketing Insights into Branded Allergy Medication Website Design

23www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insight: The Elements of High & Low Engagement

High Engagement

OTC status People + Product Images ISI Toward Bottom Less Text Social Content Prominent Indication Prominent Messaging Areas Simple Navigation Choices

Low Engagement

– Rx status– Product Images Only– ISI Centrally Located– More Text– Patient Stories– Indication Not Prominent– Compact Messaging Areas– Complex Navigation Choices

Page 24: Neuromarketing Insights into Branded Allergy Medication Website Design

24www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insight: The Elements of High & Low Engagement

Over the counter pharmaceuticals have an advantage over prescription medications• Higher levels of overall engagement

Zyrtec Claritin Benedryl Astepro Xyzal Astelin Veramyst Nasonex-0.50

0.00

0.50

1.00

1.50

2.00

2.50

3.00

2.49

2.14

1.22

0.400.21

-0.05 -0.07-0.18

Quantemo Engagement Index

Site

QEI

Page 25: Neuromarketing Insights into Branded Allergy Medication Website Design

25www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Claritin and ZyrtecOver the counter pharmaceuticals have an advantage over prescription medications• Higher levels of overall engagement• Claritin and Zyrtec had almost no associated negative emotions

Page 26: Neuromarketing Insights into Branded Allergy Medication Website Design

26www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insight: The Elements of High & Low EngagementConsumers had low neurological engagement with pages without a prominent human face• Consumers also expect to see an image of the product

Zyrtec Xyzal Nasonex Astepro Benedryl Claritin Astelin Veramyst0.00

0.20

0.40

0.60

0.80

1.00

1.20

1.40 1.33 1.33

1.12

0.730.67

0.59

0.230.15

Quantemo Neurological Index

Site

QN

I

Page 27: Neuromarketing Insights into Branded Allergy Medication Website Design

27www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Astelin and Veramyst

Consumers had low neurological engagement with pages without a prominent human face• Consumers also expect to see an image of the product

Fold

Fold

Page 28: Neuromarketing Insights into Branded Allergy Medication Website Design

28www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insight: The Elements of High & Low Engagement

A prominently placed, lengthy ISI treatment can be detrimental to consumer engagement

FoldFold

Page 29: Neuromarketing Insights into Branded Allergy Medication Website Design

29www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insight: The Elements of High & Low Engagement

A prominent, text-heavy ISI section can be detrimental to consumer engagement

FoldFold

Page 30: Neuromarketing Insights into Branded Allergy Medication Website Design

30www.otoihealth.com One to One Interactive, 2010. All rights reserved.

0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30sST Excitement LT Excitement Engagement

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

Xyzal Neuro Traces over Time

Neurological Trace and Seconds

Perc

ent

Insight: The Elements of High & Low Engagement

A prominent, lengthy ISI treatment can be detrimental to consumer engagement

• For Xyzal, neurological excitement increases while users focus on Features and ISI• Time is split in the last 15 seconds between the bottom Feature and the ISI

16-30 seconds

Page 31: Neuromarketing Insights into Branded Allergy Medication Website Design

31www.otoihealth.com One to One Interactive, 2010. All rights reserved.

0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30sST Excitement LT Excitement Engagement

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

Nasonex Neuro Traces over Time

Neurological Trace and Seconds

Perc

ent

Insight: The Elements of High & Low Engagement

• For Nasonex, neurological excitement decreases while users focus on the navigation and ISI• Time is split in the last 15 seconds between the navigation and the ISI

16-30 seconds

A prominent, lengthy ISI treatment can be detrimental to consumer engagement

Page 32: Neuromarketing Insights into Branded Allergy Medication Website Design

32www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Insight Review: The Elements of High & Low Engagement

Over the counter pharmaceuticals have an advantage over prescription medications• Higher levels of overall engagement and Zyrtec’s high long-term excitement• Claritin and Zyrtec had almost no associated negative emotions

Consumers had low neurological engagement with pages without a prominent human face• Consumers also expect to see an image of the product

A prominent, text-heavy ISI section can be detrimental to consumer engagement

Page 33: Neuromarketing Insights into Branded Allergy Medication Website Design

33www.otoihealth.com One to One Interactive, 2010. All rights reserved.

FEMALE VS. MALE ENGAGEMENT

Page 34: Neuromarketing Insights into Branded Allergy Medication Website Design

34www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Female vs. Male Engagement

Xyzal had high neurological engagement, but low overall engagement

Zyrtec Xyzal Nasonex Astepro Benedryl Claritin Astelin Veramyst0.00

0.20

0.40

0.60

0.80

1.00

1.20

1.40 1.33 1.33

1.12

0.730.67

0.59

0.230.15

Quantemo Neurological Index

Site

QN

I

Page 35: Neuromarketing Insights into Branded Allergy Medication Website Design

35www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Female vs. Male Engagement

Astelin Astepro Benedryl Claritin Nasonex Veramyst Xyzal Zyrtec0.00

0.50

1.00

1.50

2.00

2.50

Quantemo Neurological Index by Sex

Site

QN

I

Male Female

Women viewing Xyzal had the highest neurological engagement of all stimuli

Females, 16-30 seconds

Page 36: Neuromarketing Insights into Branded Allergy Medication Website Design

36www.otoihealth.com One to One Interactive, 2010. All rights reserved.

EYE TRACKING MYTHBUSTERS:THE ALLERGY EDITION

Page 37: Neuromarketing Insights into Branded Allergy Medication Website Design

37www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Eye Tracking Mythbusters: The Allergy Edition

16-30 seconds0-5 seconds 6-15 seconds

16-30 seconds

0-5 seconds

6-15 seconds

Fold

Page 38: Neuromarketing Insights into Branded Allergy Medication Website Design

38www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Eye Tracking Mythbusters: The Allergy Edition

Myth 1: People don’t read headlines – BUSTED• They do - and users expect to quickly see the indication

Myth 2: People don’t read body copy – BUSTED• They do - and early on

Myth 3: People don’t look for nor do they read the ISI – BUSTED• They do read it… albeit later

Page 39: Neuromarketing Insights into Branded Allergy Medication Website Design

39www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Eye Tracking Mythbusters: The Allergy Edition

0-5 seconds

Myth 1: People don’t read headlines – BUSTED• They do - and users expect to quickly see the indication

Page 40: Neuromarketing Insights into Branded Allergy Medication Website Design

40www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Eye Tracking Mythbusters: The Allergy Edition

0-5 seconds 6-15 seconds

0-5 seconds 6-15 seconds

0-5 seconds 6-15 seconds

Myth 2: People don’t read body copy – BUSTED• They do - and early on

Page 41: Neuromarketing Insights into Branded Allergy Medication Website Design

41www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Eye Tracking Mythbusters: The Allergy Edition

Not on AOI

Brand Logo

Top Nav1

HCP

Headline

FaceCopy

Feature

1

Feature

2 ISI

CoLogo1

CoLogo2

Site M

ap

Save CTA

Top Nav2

0

0.1

0.2

0.3

0.4

0.5

0.6

Xyzal Fixations per Second over Time

Area of Interest

Fixa

tions

per

Sec

ond

Not on AOI

Brand Logo

Top Nav

Nav

Headline

Copy

Product

Video CTA

Dr. CTA

Save CTA ISI

Site M

ap

Co Logos

0

0.1

0.2

0.3

0.4

0.5

Veramyst Fixations per Second over Time

Area of Interest

Fixa

tions

per

Sec

ond

Not on AOI

Brand Logo

Nav

Product

Headline

Face

Save CTACTA ISI

Co Logo

Site M

ap0

0.1

0.2

0.3

0.4

0.5

Nasonex Fixations per Second over Time

Area of Interest

Fixa

tions

per

Sec

ond

Not on AOI

Brand Logo

HCP

Top Nav

Product

Headline

Copy

Feature

Save CTA

Use CTA

Dr. CTA ISI

Site M

ap

Co Logo

0

0.1

0.2

0.3

0.4

0.5

Astepro Fixations per Second over Time

Area of Interest

Fixa

tions

per

Sec

ond

Not on AOI

Brand Logo

Top Nav

Headline

Product

Feature

Social C

TAHCP

Use CTA

Save CTA

Co Logo ISI

Site M

ap0

0.1

0.2

0.3

0.4

0.5

Astelin Fixations per Second over Time

Area of Interest

Fixa

tions

per

Sec

ond

6s-15s 16s-30s0s-5s

Myth 3: People don’t look for nor do they read the ISI – BUSTED• They do read it… albeit later

Page 42: Neuromarketing Insights into Branded Allergy Medication Website Design

42www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Eye Tracking Mythbusters: The Allergy Edition

Fold

Myth 3: People don’t look for nor do they read the ISI – BUSTED• They do read it… albeit later

Page 43: Neuromarketing Insights into Branded Allergy Medication Website Design

43www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Wrap Up

Methodologies and approach can be applied to any health or business vertical

Quantemo can be a critical part of brand planning, product launch, creative development and asset optimization efforts

Testing can be done on websites, landing pages, registration forms/buy flows, digital media, video, animation, email, games, kiosks and more…

Page 44: Neuromarketing Insights into Branded Allergy Medication Website Design

44www.otoihealth.com One to One Interactive, 2010. All rights reserved.

Q&A